Michel R.M. Rod Joins United Cannabis Corp Advisory Board
October 03 2017 - 08:30AM
Access Wire
Author of "Marketing ROI For Pharma" Will Drive
Commercialization of Company's Products
DENVER, CO / ACCESSWIRE / October 3, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced that Dr. Michel R.M. Rod has joined the
Company's Advisory Board to provide guidance as it seeks to
commercialize its patented Prana Bio-Nutrient Medicinal
products.
Professor Rod currently serves as Associate Dean Research &
International and PhD Program Director at the Sprott School of
Business, Carleton University in Ottawa, Canada, where his research
focuses on the collaboration amongst pharmaceutical industry,
government, and university partners in the health sector.
Dr. Rod received his Bachelor of Science in Pharmacology and
Toxicology from the University of Western Ontario, a Master of
Science in Medical Sciences from the University of Calgary, and
earned his PhD in Marketing at the University of Birmingham, UK. He
has also published more than 120 peer-reviewed articles in business
and medical journals, and conference proceedings and was the
recipient of a multi-year doctoral fellowship from the Institute of
Health Economics in Edmonton.
Earnest Blackmon, Chief Executive Officer of United Cannabis,
commented on the announcement saying, "Michel is another great
addition to our team - he literally wrote the book on marketing
pharmaceuticals! I am confident that he will be the perfect
complement to the doctors, scientists and researchers we already
have on board as we begin to navigate this next stage of
development."
Commenting on the appointment, Professor Rod added, "United
Cannabis is a progressive company that isn't constrained by a
quarterly mentality and is clearly in this business for the
long-term. Unlike many of its competitors, senior management is
assuming a traditional pharmaceutical perspective to the
development of its Prana line. That approach is now paying off as
the Company plans to commence clinical trials with a patented
product. I very much look forward to working with the entire team
in their effort to bring their products to market - in the US and
around the world."
About United Cannabis Corporation
United Cannabis is a biotechnology company dedicated to the
development of phyto-therapeutic based products supported by
patented technologies for the pharmaceutical, medical, and
industrial markets. Our products include supplements, medical
cannabis therapeutics, and pharmaceutical drugs.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation